AbbVie Inks up to $2.54B Bispecific Cancer Drug Deal with DISCO Pharma
4 Articles
4 Articles
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany’s Disco - Regional Media News
By Bhanvi Satija and Siddhi Mahatole Nov 19 (Reuters) - AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said on Thursday, marking an early-stage push by the drugmaker on next-generation bispecific therapies. Bispecific antibodies, a class of cancer medicines that bind two targets at once, have drawn increased interest from big drugmakers including Bristol Myers S…
AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets
AbbVie is partnering with Disco Pharmaceuticals, a preclinical cancer biotech, to build out its antibody-drug conjugate and T cell engager programs. The Cologne, Germany-headquartered biotech will receive $40 million upfront and up to $2.5 billion ...
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium




